New data draws upon ongoing research to highlight MammaPrint® + BluePrint® utility in early-stage breast cancer treatment planning.

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 24, 2024 – Agendia^®, Inc., announced today that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 31^st – June 4^th, 2024, in Chicago, Illinois.

The presented data underscores Agendia’s commitment to advancing individualized management of breast cancer and to providing support throughout a patient’s treatment journey. These studies add to the already robust library of clinical studies demonstrating Agendia’s MammaPrint and BluePrint effectiveness in providing reliable guidance for therapeutic considerations in early-stage breast cancer.

The two abstracts that have been selected by ASCO for oral discussion will 1) feature an investigation of underlying biology that mediates immune therapy response and, 2) will provide an evaluation of the MammaPrint Index and 3-year recurrence-free interval in patients treated with CT, with and without anthracycline. Both presentations utilize whole transcriptome data from the prospective, observational real-word evidence FLEX Study (NCT03053193).

The following are details of the abstracts that have been accepted at the ASCO 2024 Annual Meeting:

Oral Discussion

• Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

Authors: O’Shaughnessy, J., et al.

Presenter: Joyce O’Shaughnessy, MD | Baylor-Sammons Cancer Center, Texas Oncology

Session: Rapid Oral Abstract – Breast Cancer – Local/Regional/Adjuvant

Poster Discussion: Friday, May 31, 2024 | 2:45 PM – 4:15 PM CDT

Abstract #: 511

 

• Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer

Authors: Cobain, E., et al.

Presenter: Erin Cobain, MD | University of Michigan Rogel Cancer Center

Session: Oral Abstract Session – Breast Cancer – Local/Regional/Adjuvant

Poster Discussion: Monday, June 3, 2024 | 3:00 PM – 6:00 PM CDT

Abstract #: 506

Poster sessions

• Cost consequence model of the MammaPrint® (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany

Authors: Lux M.P., Sandor M. F., Hofmann V., Pronin D., Klinkhamer J.C., Müller-Huesmann H.

Presenter: Harald Müller-Huesmann | St. Josef Brothers Hospital Paderborn, Germany

Session Date & Time: Sunday, June 2, 2024 | 9:00 AM – 12:00 PM CDT

Abstract #: 534

Other Investigator Initiated Abstracts Utilizing MammaPrint + BluePrint:

• Correlation of Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancer Closely Resembles Triple Negative Breast Cancer: Results from Gene Expression Data from the ISPY2 Trial

Authors: Alejandro Rios-Hoyo; Lajos Pusztai

Session Date & Time: Sunday, 2, 2024 | 9:00AM-12:00PM CDT

Abstract #: 573

• Genomic Profile in Mexican Women with Early-Stage Breast Cancer using Mammaprint + Blueprint assay: a Retrospective Study.

Authors: Valdez, et al.

Abstract #: e12541

More information about the program can be found at the ASCO 2024 website.

Media Contact

Terri Clevenger

ICR Westwicke Healthcare PR

Tel: 203.682.8297

Terri.Clevenger@Westwicke.com